Keiko Tanimura - Concepedia

Author

Keiko Tanimura

Kyoto Prefectural University of Medicine ORCID

Also Known As

K. Tanimura, KEIKO TANIMURA, Keiko Tanimura, Tanimura K, Tanimura Keiko

104

Publications

Citations

H-Index

Concepts

All Affiliations

Kyoto Prefectural University of Medicine Kyoto first Red Cross hospital Japanese Red Cross Society Kyoto Daini Hospital Kanazawa University Suita Tokushukai Hospital

About

Keiko Tanimura is an author at Kyoto Prefectural University of Medicine specializing in lung cancer, radiation oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	133
2	Cell Biology	2	2	46
3	Immunology	1	1	87
4	Pathology	1	1	87
5	Cancer Genetics	1	1	27

Keiko Tanimura

Publications

907

Citations

H-Index

Page 1

	Year	Citations
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Nature Communications	2019	351
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer Tadaaki Yamada, Soichi Hirai, Yuki Katayama, Cancer Medicine	2019	114
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Clinical Cancer Research	2020	108
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer Naoya Nishioka, Junji Uchino, Soichi Hirai, Journal of Clinical Medicine Advanced NsclcNon-small-cell Lung CancerMedicineCancer ManagementImmunology	2019	87
Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients Yuki Katayama, Tadaaki Yamada, Yusuke Chihara, Scientific Reports	2020	37
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, npj Precision Oncology Systems BiologyOncologyAlk-rearranged Lung CancerMedicineKinase Inhibitors	2023	27
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, JAMA Network Open	2023	27
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features Keiko Tanimura, Tadaaki Yamada, Koutaroh Okada, npj Precision Oncology	2022	24
Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Thoracic Cancer	2019	20
High levels of <scp>AXL</scp> expression in untreated <scp><i>EGFR</i></scp>‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib Akihiro Yoshimura, Tadaaki Yamada, Masakuni Serizawa, Cancer Science	2022	20

Page 1